CD66b As a Prognostic and Predictive Biomarker in Patients with Non-small Cell Lung Cancer Treated with Checkpoint Blockade Immunotherapy

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2023 Mar 14

PMID 36915573

Authors

Swati Jain

Kevin Ma

Luc G T Morris

Affiliations

Soon will be listed here.

Citing Articles

Inhibition and evasion of neutrophil microbicidal responses by .

Hanford H, Price C, Uriarte S, Abu Kwaik Y mBio. 2024; 16(2):e0327424.

PMID: 39679679 PMC: 11796426. DOI: 10.1128/mbio.03274-24.

Spatial proteomic profiling of tumor and stromal compartments in non-small-cell lung cancer identifies signatures associated with overall survival.

Naei V, Monkman J, Sadeghirad H, Mehdi A, Blick T, Mullally W Clin Transl Immunology. 2024; 13(7):e1522.

PMID: 39026528 PMC: 11257771. DOI: 10.1002/cti2.1522.

References

Moutafi M, Martinez-Morilla S, Divakar P, Vathiotis I, Gavrielatou N, Aung T . Discovery of Biomarkers of Resistance to Immune Checkpoint Blockade in NSCLC Using High-Plex Digital Spatial Profiling. J Thorac Oncol. 2022; 17(8):991-1001. PMC: 9356986. DOI: 10.1016/j.jtho.2022.04.009. View

Kim H, Park S, Seo S, Jung I, Yoon H, Gabrilovich D . The Ratio of Peripheral Regulatory T Cells to Lox-1 Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. Am J Respir Crit Care Med. 2018; 199(2):243-246. PMC: 6835091. DOI: 10.1164/rccm.201808-1502LE. View

Furumaya C, Martinez-Sanz P, Bouti P, Kuijpers T, Matlung H . Plasticity in Pro- and Anti-tumor Activity of Neutrophils: Shifting the Balance. Front Immunol. 2020; 11:2100. PMC: 7492657. DOI: 10.3389/fimmu.2020.02100. View

Shields M, Marin-Acevedo J, Pellini B . Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Decade of Progress. Am Soc Clin Oncol Educ Book. 2021; 41:1-23. DOI: 10.1200/EDBK_321483. View

Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J . Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(6):e98259. PMC: 4048155. DOI: 10.1371/journal.pone.0098259. View

Arasanz H, Bocanegra A, Morilla I, Fernandez-Irigoyen J, Martinez-Aguillo M, Teijeira L . Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer. Cancers (Basel). 2022; 14(16). PMC: 9406164. DOI: 10.3390/cancers14163846. View

Lecot P, Sarabi M, Pereira Abrantes M, Mussard J, Koenderman L, Caux C . Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Front Immunol. 2019; 10:2155. PMC: 6764113. DOI: 10.3389/fimmu.2019.02155. View

Carus A, Ladekarl M, Hager H, Pilegaard H, Nielsen P, Donskov F . Tumor-associated neutrophils and macrophages in non-small cell lung cancer: no immediate impact on patient outcome. Lung Cancer. 2013; 81(1):130-7. DOI: 10.1016/j.lungcan.2013.03.003. View

Zugazagoitia J, Gupta S, Liu Y, Fuhrman K, Gettinger S, Herbst R . Biomarkers Associated with Beneficial PD-1 Checkpoint Blockade in Non-Small Cell Lung Cancer (NSCLC) Identified Using High-Plex Digital Spatial Profiling. Clin Cancer Res. 2020; 26(16):4360-4368. PMC: 7442721. DOI: 10.1158/1078-0432.CCR-20-0175. View

10.

Bronte V, Brandau S, Chen S, Colombo M, Frey A, Greten T . Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7:12150. PMC: 4935811. DOI: 10.1038/ncomms12150. View

11.

Lu S, Stein J, Rimm D, Wang D, Bell J, Johnson D . Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis. JAMA Oncol. 2019; 5(8):1195-1204. PMC: 6646995. DOI: 10.1001/jamaoncol.2019.1549. View

12.

Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C, Mouroux J . Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2011; 118(6):1726-37. DOI: 10.1002/cncr.26456. View

13.

Rakaee M, Busund L, Paulsen E, Richardsen E, Al-Saad S, Andersen S . Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer. Oncotarget. 2016; 7(44):72184-72196. PMC: 5342153. DOI: 10.18632/oncotarget.12360. View

14.

Yu H, Boyle T, Zhou C, Rimm D, Hirsch F . PD-L1 Expression in Lung Cancer. J Thorac Oncol. 2016; 11(7):964-75. PMC: 5353357. DOI: 10.1016/j.jtho.2016.04.014. View

15.

Faget J, Peters S, Quantin X, Meylan E, Bonnefoy N . Neutrophils in the era of immune checkpoint blockade. J Immunother Cancer. 2021; 9(7). PMC: 8728357. DOI: 10.1136/jitc-2020-002242. View

16.

Kargl J, Zhu X, Zhang H, Yang G, Friesen T, Shipley M . Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC. JCI Insight. 2019; 4(24). PMC: 6975266. DOI: 10.1172/jci.insight.130850. View